Investment bank UBS has boosted its sales forecast for Neurocrine Biosciences' flagship drug Ingrezza, signaling confidence in the treatment's continued growth despite headwinds elsewhere in the company's pipeline.
UBS now expects Ingrezza to generate $2.80 billion in sales by 2026, up from its previous estimate of $2.75 billion and slightly above the $2.78 billion consensus among analysts. The revision comes as the bank also anticipates that growth for Neurocrine's newer drug Vykat will cool and that few major clinical trial readouts will occur before the second half of 2027.
What's Driving the Optimism?
Ingrezza is a once-daily oral medication approved to treat tardive dyskinesia, a movement disorder often caused by long-term use of antipsychotic drugs. It is Neurocrine's top revenue generator and a key driver of the company's stock performance.
UBS points to two near-term catalysts that could boost Ingrezza prescriptions. First, changes in insurance coverage for Teva Pharmaceutical Industries' rival drug Austedo may steer more patients toward Ingrezza. Second, Neurocrine has expanded its sales force by roughly 30%, which the bank believes could lift prescription trends and eventually lead to higher company guidance.
The bank also sees potential for Ingrezza to capture additional market share as physicians and patients become more familiar with the drug's profile.
Vykat Growth Slows, Pipeline Distant
While Ingrezza looks strong, Neurocrine's newer drug Vykat—approved for a different neurological condition—is expected to see its growth rate decelerate. Vykat launched more recently and had been a source of excitement, but UBS now models a more tempered trajectory.
Beyond the two commercial drugs, Neurocrine's pipeline includes several experimental treatments, but UBS notes that major clinical trial results are unlikely before the second half of 2027. That means investors may have to wait years for the next potential blockbuster, placing even more weight on Ingrezza's performance in the near term.
What It Means for Investors
For everyday investors, the UBS analysis highlights how a single drug can dominate a biotech company's fortunes. Ingrezza is the engine that powers Neurocrine's revenue and earnings, and any changes in its outlook can move the stock significantly.
The raised forecast suggests that Wall Street sees room for Ingrezza to outperform current expectations, driven by competitive dynamics and sales execution. However, the lack of near-term pipeline catalysts means the company's share price may remain tied to quarterly Ingrezza sales figures and prescription data.
Investors should also watch for updates on insurance coverage decisions and competitor moves, as these can quickly alter the landscape. The broader biotech sector has seen mixed performance lately, with some companies benefiting from strong drug sales while others struggle with pipeline setbacks.
As always, it's important to consider diversification. A single-stock bet on a biotech firm carries higher risk than a broad market fund, especially when the company's value hinges on one product.
For more on how analysts are viewing other companies, see our coverage of Celsius Core Sales Slow as SKU Trim Bites, but Alani Nu Growth Offers Hope: UBS and Jack in the Box's 'JACK on Track' Plan: Closing Weak Stores to Tackle $1.6 Billion Debt.
